Phosphonic acid compounds as inhibitors of serine proteases

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S022000

Reexamination Certificate

active

07459461

ABSTRACT:
The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.

REFERENCES:
patent: 4704382 (1987-11-01), Fowler et al.
patent: 4822780 (1989-04-01), Tsuda et al.
patent: 5508273 (1996-04-01), Beers et al.
patent: 6080738 (2000-06-01), Akahoshi et al.
patent: 6528514 (2003-03-01), Kobayashi et al.
patent: 633914 (1963-12-01), None
patent: WO 97/03679 (1997-02-01), None
patent: WO 03/035654 (2003-05-01), None
Sands et. al., “LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury”, Expert Opinion on Investigational Drugs, pp. 1907-1916, 1999.
CA 137:103177, “Elastase Inhibitors”, Journal de la Societe de Biologie (2001), 195 (2), 143-150.
Ca 126:234793, “Structure and function of thrombin receptor”, Ishii et. al., Nippon Domyaku Koka Gakkai, 1997.
Pharmaceutical salts, Berge S. et al 1977.
Schoofs et. al., “Trypsin and Chymotrypsin Inhibitors in Insects and Gut Leeches”, Current Pharmaceutical Design, 8, 483-491 8, 2002.
Chambers et. al., “Leukotriene antagonists: patents highlights 1996-1998”, Expert Opinion on Therapeutic Patents, 1999, 9 (1 19-26.
Numerof, et. al., “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis—Tryptase Inhibitors: a novel class of anti-inflammatory drugs”, Expert Opinion on Investigational Drugs (1997), 6 (7), pp. 811-817.
Ahn, et. al., “Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restonosis and Inflammatory Diseases”, Current Pharmaceutical Design, 2003, 9, 2349-2365.
PCT International Preliminary ExaminationReport for Appln. No. PCT/US02/33206 dated Aug. 8, 2003.
Yao, Yu-Lin, “Association between the Expression of Mast Cell Chymase and Intraperitoneal Adhesion Formation in Mice,” Journal of Surgical Research 92, 4-44 (2000).
Sands, Howard et al., “LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury,” Exp. Opin. Invest. Drugs (1999) 8(11);1907-1916.
Akahoshi, Fumihiko et al., “Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiles of Nonpeptidic Difluoromethylene Ketones as Novel Inhibitors of Human Chymase,” J. Med. Chem. 2001, 44, 1297-1304.
de Garavilla, et al., “A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase,” The Journal of Biological Chemistry, 280(18): 18001-18007 (2005).
Willem I. de Boer, “Perspectives for cytokine antagonist therapy in COPD,” Drug Discovery Today, 10(2): 93-106 (2005).
Peter J. Barnes, “New Treatments for COPD,” Nature Reviews, 1: 437-446 (2002).
Henning, et al., “Synthesis and Neuroleptic Activity of a Series of 1-[1-(Benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone Derivatives,” Journal of Medicinal Chemistry, 30: 814-819 (1987).
PCT International Search Report, PCT/US 02/33206 Oct. 17, 2002.
Bioorganic&Med. Chem. Lett., 1995, 5, (16), 1801-1806.
Ref. International J. Pharm.1986, 33, 201-217.
J. Pharm. Sci., Jan. 1977, 66(1), p. 1-19.
Greco, Michael N. et al., “Nonpeptide Inhibitors of Cathepsin G: Optimization of a Novel.beta—Ketophosphonic Acid Lead by Structure-Bassed Drug Design”, Journal of the American Chemical Society, 2002 124(15), pp. 3810-3811.
De Lombaert S., et al, Non-Peptidic Inhibitors of Neutral Endopeptidase 24.11, Design and Pharmacology of Orally Active Phosphonate Prodrugs,Bioorganic and Medicinal Chemistry Letters, 1995 5(2), 151-154.
De Lombaert S., et al,N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generatrion Neutral Endopeptidase (NEP, EC 3.424.11) Inhibitors,J. Med. Chem., 1994, 37, 498-511.
Katritsky, et. al.,Org. Prep. Proced. Int., 1990, 22(2), 209-213.
Deprele, et al.,J. Am. Chem. Soc., 2002, 124, 9386-9387.
Steininger,Chem. Ber., 1963, 96, 3184-3194 (w/English-language translation of Abstract).
Abraham, W.M., Pharmacology of allergen-induced early and late airway responses and antigen-induced airway hyperresponsiveness in allergic sheep,Pulmonary Pharmacology, 1989, 2, 33-40.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Phosphonic acid compounds as inhibitors of serine proteases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphonic acid compounds as inhibitors of serine proteases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphonic acid compounds as inhibitors of serine proteases will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4031249

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.